Search results for "Response"

showing 10 items of 4136 documents

Anti-muscarinic drugs as preventive treatment of exercise-induced bronchoconstriction (EIB) in children and adults.

2020

Regular physical activity is strongly recommended to prevent chronic respiratory diseases, including asthma. On the other hand, vigorous physical training may trigger airway symptoms and bronchoconstriction. The transient airway narrowing occurring because of exercise is named exercise-induced bronchoconstriction (EIB). Despite management according to guidelines, a significant proportion of patients experiences uncontrolled EIB, which thus represents a relevant unmet medical need. In particular, although prevention and treatment of EIB are effectively based on the use of beta-2 bronchodilator drugs, high heterogeneity in individual responses has been reported. Furthermore, even though beta-…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classBronchoconstrictionMuscarinic Antagonists03 medical and health sciencesYoung Adult0302 clinical medicineBronchodilatorAdministration InhalationRespiratory HypersensitivityMedicineAdrenergic DrugsHumans030212 general & internal medicineIntensive care medicineAdverse effectChildAsthmabusiness.industrymedicine.diseaseResponse VariabilityExercise-induced bronchoconstrictionBronchodilator AgentsAnti-muscarinic030228 respiratory systemDelayed-Action PreparationsSettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREAnti muscarinicSystematic reviewBronchoconstrictionFemalemedicine.symptomAirwaybusinesshuman activitiesPhysical Conditioning HumanRespiratory medicine
researchProduct

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma.

2002

The ability of omalizumab, an anti-immnoglobulin-E agent, to maintain long-term disease control in patients with moderate-to-severe allergic asthma was investigated in a 24-week double-blind extension to a 28-week core trial. During the extension, 483 of the initial 546 patients were maintained on randomised treatment and the lowest sustainable dose of beclomethasone dipropionate (BDP) as established during the steroid-reduction phase of the core trial. The use of concomitant asthma medication was permitted and investigators were allowed to adjust the BDP dose or switch patients from BDP to other asthma medications if deemed necessary. More omalizumab-treated patients (33.5%) than placebo-t…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAllergyTime FactorsAdolescentOmalizumabOmalizumabImmunoglobulin EPlaceboAntibodies Monoclonal HumanizedSeverity of Illness Indexlaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineHypersensitivityHumansAnti-Asthmatic AgentsAdverse effectChildAsthmaAgedbiologyDose-Response Relationship Drugbusiness.industryBeclomethasoneAntibodies MonoclonalMiddle Agedmedicine.diseaseAsthmaSurgeryAntibodies Anti-IdiotypicTreatment OutcomeConcomitantbiology.proteinFemalebusinessmedicine.drugFollow-Up StudiesThe European respiratory journal
researchProduct

Effect of body weight on the volume of distribution of theophylline.

1988

The volume of distribution (Vd) of theophylline and the relevant aminophylline loading dose (LD) are usually calculated on the basis of total body weight (TBW). In obese subjects it has been suggested that lean or ideal body weight (IBW) is the best predictor. In a sample of 40 acutely ill asthmatic patients (aged 22 to 78 yr, weighing 45 to 176 kg) we measured Vd and found that (1) it increases with TBW, (2) it cannot be accurately predicted from either TBW or IBW alone by a simple regression analysis. Power functions have been usefully applied in comparing the pharmacokinetics of animal species, including humans, with different body mass. In our sample, data were best fitted by the equati…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyBody weightLoading doseAnimal sciencePharmacokineticsTheophyllineInternal medicinemedicineHumansTheophyllineObesityAnimal speciesAgedVolume of distributionDose-Response Relationship Drugbusiness.industryBody WeightRegression analysisMiddle AgedAsthmaEndocrinologyRegression AnalysisAminophyllineFemalebusinessmedicine.drugLung
researchProduct

A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.

2008

This dose-ranging study assessed the bronchodilator efficacy and tolerability of indacaterol, a novel once-daily inhaled beta2-agonist, in subjects clinically diagnosed with COPD. Comparative data with tiotropium were collected. In the double-blind, core period of the study, 635 subjects with COPD (prebronchodilator FEV(1)40% of predicted and > or =1.0L; FEV1/FVC <70%) were randomized to receive indacaterol 50, 100, 200 or 400microg or placebo via multi-dose dry powder inhaler, or indacaterol 400microg via single-dose dry powder inhaler, once daily for 7 days. After completing double-blind treatment and washout, a subset of subjects from each treatment group entered an open-label extension …

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyEfficacymedicine.drug_classScopolamine DerivativesQuinolonesFEV1/FVC ratioPulmonary Disease Chronic ObstructiveDouble-Blind MethodBronchodilatorForced Expiratory VolumeAdministration InhalationCOPDMedicineHumansTiotropium BromideIndacaterolAgedCOPDDose-Response Relationship Drugbusiness.industryTiotropiumTiotropium bromideMiddle AgedDose-ranging studymedicine.diseaseDry-powder inhalerrespiratory tract diseasesSurgeryBronchodilator AgentsTreatment OutcomeTolerabilityDoseAnesthesiaIndansIndacaterolFemaleSafetybusinessmedicine.drugRespiratory medicine
researchProduct

Is the patient's baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen?

2011

Objective: Baseline inhaled corticosteroid (ICS) dose may be a factor for prescribers to consider when they select a budesonide/formoterol maintenance and reliever therapy regimen for symptomatic asthmatics. Methods: A 6-month randomized study compared two maintenance doses of budesonide/formoterol 160/4.5 µg, 1 × 2 and 2 × 2, plus as needed, in 8424 asthma patients with symptoms when treated with ICS ± an inhaled long-acting β2-agonist (LABA). In the total study population, 1339 (17%) were high-dose ICS (HD) users (≥1600 µg/day budesonide). This HD stratum was compared with the rest of the study population, divided into low-dose (LD; 400 µg/day) and medium-dose strata (MD; 401–1599 µg/day…

Pulmonary and Respiratory MedicineBudesonideAdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classSeverity of Illness Indexlaw.inventionYoung AdultRandomized controlled triallawAdrenal Cortex HormonesInternal medicineSurveys and QuestionnairesAdministration InhalationmedicineBudesonide Formoterol Fumarate Drug CombinationHumansPharmacology (medical)Anti-Asthmatic AgentsBudesonideAsthmaAgedlcsh:RC705-779Aged 80 and overDose-Response Relationship Drugbusiness.industrylcsh:Diseases of the respiratory systemMiddle Agedmedicine.diseaseAsthmaRegimenDrug CombinationsTreatment OutcomeBudesonide/formoterolAsthma Control QuestionnaireEthanolaminesAnesthesiaCorticosteroidFemaleFormoterolbusinessmedicine.drugTherapeutic advances in respiratory disease
researchProduct

Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity.

2013

Background Guidelines for chronic obstructive pulmonary disease (COPD) recommend that treatment choices be based partly on symptoms. Methods A post-hoc analysis of pooled data from clinical studies compared the efficacy and safety of once-daily inhaled bronchodilators indacaterol (150 and 300 μg) and open-label tiotropium (18 μg) according to baseline dyspnoea severity on the modified Medical Research Council (mMRC) scale in patients with COPD (mMRC scores <2 = ‘less dyspnoea’; scores ≥2 = ‘more dyspnoea’). Outcomes were assessed after 26 weeks. Results The analysis included 3177 patients. In patients with less dyspnoea: indacaterol (both doses) improved 24-h post-dose (‘trough’) forced exp…

Pulmonary and Respiratory MedicineCopd patientsScopolamine DerivativesPulmonary diseaseQuinolonesPlaceboPulmonary Disease Chronic ObstructiveForced Expiratory VolumeMedicineHumansPharmacology (medical)In patientPooled dataTiotropium BromideRandomized Controlled Trials as TopicCOPDDose-Response Relationship Drugbusiness.industryBiochemistry (medical)Patient AcuityTreatment optionsmedicine.diseaserespiratory tract diseasesBronchodilator AgentsDyspneaAnesthesiaDelayed-Action PreparationsIndansIndacaterolbusinessmedicine.drugPulmonary pharmacologytherapeutics
researchProduct

Influence of endothelial nitric oxide on neurogenic contraction of human pulmonary arteries.

1995

The present study was designed to investigate the contribution of the endothelium and that of the L-arginine pathway on the contractile responses of isolated human pulmonary arteries to electrical field stimulation (EFS) and noradrenaline. Isometric tension was measured in artery rings obtained from portions of human lung after thoracic surgery for removal of lung carcinoma (18 patients). Electrical field stimulation (EFS) induced frequency-dependent contractions of isolated human pulmonary arteries which were abolished by tetrodotoxin, guanethidine and prazosin (all at 10(-6) M). The increases in tension were of greater magnitude in arteries denuded of endothelium. NG-nitro-L-arginine meth…

Pulmonary and Respiratory MedicineGuanethidineMalemedicine.medical_specialtyEndotheliumTetrodotoxinIn Vitro TechniquesPulmonary ArteryArginineNitric OxideNitric oxidechemistry.chemical_compoundNorepinephrineInternal medicinemedicine.arterymedicinePrazosinHumansGuanethidineAgedDose-Response Relationship Drugbusiness.industryPrazosinElectric StimulationEndocrinologymedicine.anatomical_structureNG-Nitroarginine Methyl EsterchemistryAnesthesiaPulmonary arteryCirculatory systemEndothelium VascularNitric Oxide SynthasebusinessAdrenergic FibersAdrenergic alpha-AgonistsBlood vesselmedicine.drugArteryMuscle ContractionThe European respiratory journal
researchProduct

Theophylline suppresses the release of tumour necrosis factor-alpha by blood monocytes and alveolar macrophages.

1994

The purpose of this study was to evaluate the effect of theophylline on tumour necrosis factor-alpha (TNF-alpha) release by human blood monocytes (BMo), and rat BMo and alveolar macrophages (AM). BMo and AM were incubated in the absence or presence of theophylline, and the cell-free supernatants were harvested and tested for TNF-alpha activity by bioassay. Theophylline dose-dependently reduced TNF-alpha release by human BMo: significant inhibition was observed at 100 microns (41 +/- 5.9% of controls) and at 50 microns (59 +/- 4.8% of controls), while the inhibitory activity of theophylline at 10 microns (71 +/- 8.9% of controls) was not statistically significant. This activity was maximal a…

Pulmonary and Respiratory MedicineLipopolysaccharidesMalemedicine.medical_specialtyNecrosismedicine.drug_classmedicine.medical_treatmentGene ExpressionIn Vitro TechniquesTheophyllineBronchodilatorInternal medicineMacrophages AlveolarmedicineAnimalsHumansTheophyllineRats WistarDose-Response Relationship Drugbusiness.industryTumor Necrosis Factor-alphaMonocytemedicine.diseaseBlotting NorthernRatsmedicine.anatomical_structureEndocrinologyCytokineBronchial hyperresponsivenessLeukocytes MononuclearTumor necrosis factor alphaPulmonary alveolusmedicine.symptombusinessmedicine.drugThe European respiratory journal
researchProduct

Cardioprotective effects of the serine protease inhibitor aprotinin after regional ischemia and reperfusion on the beating heart.

2002

AbstractObjective: Early coronary reperfusion of the ischemic myocardium is a desired therapeutic goal to preserve myocardium. However, reperfusion itself contributes to an additional myocardial injury (ie, reperfusion injury), which has been attributed to neutrophil infiltration with subsequent release of proteases and oxygen-derived radicals. We studied the effects of the serine protease inhibitor aprotinin (Trasylol) on myocardial ischemia and reperfusion in a rat model. Methods: The effects of aprotinin (5000 and 20,000 U/kg) were examined in vivo in a rat model of regional myocardial ischemia (20 minutes) and long-term reperfusion (24 hours). Cardioprotecive effects were determined by …

Pulmonary and Respiratory MedicineMaleProteasesCardiotonic AgentsSerine Proteinase InhibitorsNeutrophilsHeart VentriclesIschemiaMyocardial IschemiaApoptosisMyocardial ReperfusionMyocardial Reperfusion InjuryPharmacologyRats Sprague-DawleyLeukocyte CountAprotininIn vivoMedicineAnimalsAprotininCreatine KinasePeroxidaseCardioprotectionbiologyDose-Response Relationship Drugbusiness.industryMyocardiumModels Cardiovascularmedicine.diseaseCombined Modality TherapyRatsDisease Models AnimalTreatment OutcomeEnzyme inhibitorAnesthesiabiology.proteinSurgeryCreatine kinaseCardiology and Cardiovascular MedicinebusinessReperfusion injuryBiomarkersmedicine.drugThe Journal of thoracic and cardiovascular surgery
researchProduct

Direct effect of cigarette smoke on human pulmonary artery tension.

2010

The effect of chronic cigarette smoke on pulmonary artery (PA) tension has been studied extensively; nevertheless, the direct effect of cigarette smoke is poorly understood. We investigated the direct effect of cigarette smoke extract (CSE) on PA tension in non-smokers, smokers, and COPD patients in vitro. PA samples from 35 patients who underwent lung resection were examined by measuring isometric tension in response to increasing serotonin concentrations. CSE dose dependently inhibited the response to serotonin in smokers and COPD patients, and to a lesser extent in non-smokers. CSE-induced relaxation was similarly inhibited by the nonspecific nitric oxide synthase (NOS) inhibitor l-NOARG…

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtySerotoninContraction (grammar)In Vitro TechniquesPulmonary ArteryNitroarginineMuscle Smooth VascularFEV1/FVC ratioPulmonary Disease Chronic ObstructiveEnosInternal medicinemedicine.arterySmokeparasitic diseasesTobaccomedicineHumansPharmacology (medical)5-HT receptorCOPDbiologyDose-Response Relationship Drugbusiness.industryLysineBiochemistry (medical)biology.organism_classificationmedicine.diseaserespiratory tract diseasesNitric oxide synthaseEndocrinologyAnesthesiaPulmonary arterybehavior and behavior mechanismsbiology.proteinFemaleSerotoninNitric Oxide SynthasebusinessMuscle ContractionPulmonary pharmacologytherapeutics
researchProduct